The effect of chronic carnosine treatment on serum levels of glucose and lipids and blood pressure in an experimental model of hyperlipidemia in mice

Document Type : Original Article

Authors

1 Department of Cardiology and Internal Medicine, School of Medicine, Shahed University, Tehran, Iran

2 Department of Physiology, School of Medicine, Shahed University, Tehran, Iran.

3 School of Medicine, Shahed University, Tehran, Iran.

Abstract

Background and Objective: Chronic hyperlipidemia accompanies various complications in the body. With regard to protective and beneficial effect of carnosine in metabolic disorders, this study was conducted to evaluate its effect on serum lipids and blood pressure in an experimental model of hyperlipidemia in mice.
 Materials and Methods: Mice were divided into five groups, i.e. control, high-dose carnosine-treated control, hyperlipidemic, and two carnosine-treated (125 and 250 mg/kg) hyperlipidemic groups. Carnosine was administered i.p. from 8th week after hyperlipidemia induction for 4 weeks.
 Results: Carnosine did not cause any significant reduction of serum glucose, there was a significant increase in serum total cholesterol and triglyceride in hyperlipidemic group as compared to control (p<0.05-0.01) and carnosine at a high dose significantly decreased it (p<0.05). Regarding serum HDL cholesterol, carnosine treatment did not significantly change it. In contrast, hyperlipidemia significantly increased LDL-cholesterol (p<0.05) and carnosine at a dose of 250 mg/kg significantly lowered it (p<0.05). In addition, hyperlipidemic mice has a significantly higher systolic blood pressure (p<0.05) and carnosine treatment did not significantly change it.
 Conclusion: Administration of carnosine to hyperlipidemic mice does not affect serum glucose level and systolic blood pressure and significantly lowers serum total cholesterol, LDL-cholesterol, and triglyceride level.

Keywords

References

1. Sharma M. Combination therapy for dyslipidemia. Curr Opin Cardiol 2011; 26(5):420-3.
 2. Mashimo Y., Teramoto T. Principles pharmacotherapy for dyslipidemia associated with metabolic syndrome. Nihon Rinsho. 2011;69:601-6.
 3. Kopin L, Lowenstein C. In the clinic: Dyslipidemia. Ann Intern Med 2010; 153(3): ITC21.
 4. Paraskevas KI, Karatzas G, Pantopoulou A, Iliopoulos DG, Perrea D. Targeting dyslipidemia in the metabolic syndrome: an update. Curr Vasc Pharmacol 2010; 8: 450-63.
 5. Raal FJ. Pathogenesis and management of the dyslipidemia of the metabolic syndrome. Metab Syndr Relat Disord 2009; 7: 83-88.
 6. Iughetti L, Bruzzi P, Predieri B. Evaluation and management of hyperlipidemia in children and adolescents. Curr Opin Pediatr 2010; 22: 485-93.
 7. Chanoine P, Spector ND. Hyperlipidemia, eating disorders, and smoking cessation. Curr Opin Pediatr 2008; 20: 734-9.
 8. Jain KS, Kathiravan MK, Somani RS, Shishoo CJ. The biology and chemistry of hyperlipidemia. Bioorg Med Chem 2007; 15: 4674-99.
 9. Fonseca VA. The metabolic syndrome, hyperlipidemia, and insulin resistance. Clin Cornerstone 2005; 7: 61-72.
 10. Nobukuni Y, Higashikawa F, Miyagawa K, Eboshida A. Hyperlipidemia: complex pathophysiology caused by multiple genetic and environmental factors--in considering the approaches to preventive medicine. Nihon Eiseigaku Zasshi 2005; 60: 426-41.
 11. Eaton CB. Hyperlipidemia. Prim Care. 2005; 32: 1027-55.
 12. Seishima M. Guideline for hyperlipidemia. Rinsho Byori 2003; 51: 576-80.
 13. Kanani PM, Sperling MA. Hyperlipidemia in adolescents. Adolesc Med 2002; 13: 37-52.
 14. Farnier M. Safety review of combination drugs for hyperlipidemia. Expert Opin Drug Saf 2011; 10: 363-71.
 15. Hasani-Ranjbar S, Nayebi N, Moradi L, Mehri A, Larijani B, Abdollahi M. The efficacy and safety of herbal medicines used in the treatment of hyperlipidemia; a systematic review. Curr Pharm Des 2010; 16: 2935-47.
16. Reindl EK, Wright BM, Wargo KA. Alternate-day statin therapy for the treatment of hyperlipidemia. Ann Pharmacother 2010; 44: 1459-70.
17. Paras C, Hussain MM, Rosenson RS. Emerging drugs for hyperlipidemia. Expert Opin Emerg Drugs 2010; 15: 433-51.
18. Kreisberg RA, Oberman A. Medical management of hyperlipidemia/dyslipidemia. J Clin Endocrinol Metab 2003; 88: 2445-61.
19. Henley E, Chang L, Hollander S. Treatment of hyperlipidemia. J Fam Pract 2002; 51: 370-6.
20. Boldyrev AA, Stvolinsky SL, Fedorova TN, Suslina ZA. Crnosine as a natural antioxidant and geroprotector from molecular mechanisms to clinical trials. Rejuvenation Res 2010; 13: 156-8.
21. Hipkiss AR. Carnosine and its possible roles in nutrition and health. Adv Food Nutr Res 2009; 57: 87-154.
22. Boldyrev AA, Stvolinskiĭ SL, Fedorova TN. Carnosine: endogenous physiological corrector of antioxidative system activity. Usp Fiziol Nauk 2007; 38: 57-71.
23. Zieba R. Carnosine--biological activity and perspectives in pharmacotherapy. Wiad Lek 2007; 60: 73-9.
24. Volkov OV. Biological role of carnosine and its use in ophthalmology (mini-review. Biomed Khim 2005; 51: 481-4.
25.Guiotto A, Calderan A, Ruzza P, Borin G. Carnosine and carnosine-related antioxidants: a review. Curr Med Chem 2005; 12: 2293-315
26. Reddy VP, Garrett MR, Perry G, Smith MA. Carnosine: a versatile antioxidant and antiglycating agent. Sci Aging Knowledge Environ 2005; 18: 12.
27. Ozdogan K, Taskın E, Dursun N. Protective effect of carnosine on adriamycin-induced oxidative heart damage in rats. Anadolu Kardiyol Derg. 2011; 11: 3-10.
28. Aydogan S, Yapislar H, Artis S, Aydogan B. Impaired erythrocytes deformability in H(2)O(2)-induced oxidative stress: protective effect of L-carnosine. Clin Hemorheol Microcirc 2008; 39: 93-8.
29. Kurata H, Fujii T, Tsutsui H, Katayama T, Ohkita M, Takaoka M, et al. Renoprotective effects of l-carnosine on ischemia/reperfusion-induced renal injury in rats. J Pharmacol Exp Ther 2006; 319: 640-7.
30. Peters V, Schmitt CP, Zschocke J, Gross ML, Brismar K, Forsberg E. Carnosine treatment largely prevents alterations of renal carnosine metabolism in diabetic mice. Amino Acids 2012; 42(6):2411-6.
31. Duchemin S, Belanger E, Wu R, Ferland G, Girouard H. Chronic perfusion of angiotensin II causes cognitive dysfunctions and anxiety in mice. Physiol Behav 2012; 12: 330-7.
Daneshvar Medicine
Volume 20, Issue 5 - Serial Number 102
January and February 2013
Pages 9-16

Files

Share

How to cite

Statistics